Navigation Links
Bionovo Announces Third Quarter 2009 Highlights and Financial Results
Date:11/5/2009

nufacturing and analytical strategy for guaranteeing the consistency of its drug products. The Company is currently concluding work on the analytical method application and the commercial scale manufacturing batches.
  • Bionovo presented the positive results of its Phase 2 clinical trial of Menerba to the international women's health community at the 8th Annual European Society for Gynecology (EGS) in Rome, Italy. The overall reaction of the European scientific, clinical, and pharmaceutical community was extremely positive and demonstrated an international interest in finding a safer alternative to hormone therapy for the treatment of menopausal vasomotor symptoms.
  • The Company presented the results of a study on the effects of two plant-derived, tissue-selective estrogen receptor alpha (ERa) modulators (TSERaM) on menopausal obesity at the 20th Annual Meeting of the North American Menopause Society. In this study, plant-derived TSERaMs, like estrogens, were shown to reduce body fat in mice, but while estrogens also caused cell proliferation in the mammary gland and uterus, the plant-derived TSERaMs did not elicit these potentially cancer-causing side effects. These results suggest that the development of botanically-derived, tissue-selective ERa modulators could result in a safer alternative for the treatment of menopausal weight gain, a condition that can lead to the development of metabolic syndrome, a combination of risk factors for cardiovascular disease and diabetes.
  • Bionovo published a paper describing the molecular mechanisms underlying the selective cytotoxic activity of its preclinical drug candidate BN108 and its active compound, timosaponin AIII (TAIII), in the peer-reviewed, open-access journal, Public Library of Science One. BN108 and TAIII kill tumor cells by eliciting two responses: first, they inhibit mTORC1, an oncogenic pathway that is abnormally activated in many tumors, and second, they induce a profound stress in the en
    '/>"/>

  • SOURCE Bionovo, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2009 Financial Results on Thursday, November 5, 2009
    2. Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta
    3. Bionovo Announces Second Quarter 2009 Highlights and Financial Results
    4. Bionovos Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
    5. Bionovo Announces First Quarter 2009 Highlights and Financial Results
    6. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
    7. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
    8. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
    9. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
    10. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
    11. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... Sept. 30, 2014  Alimera Sciences, Inc. (NASDAQ: ... in the research, development and commercialization of prescription ophthalmic ... million advance from Hercules Technology Growth Capital, Inc. (NYSE: ... second and final advance under the Loan and Security ... Kingdom , Alimera Sciences Limited, entered into with ...
    (Date:9/30/2014)... 30, 2014 A study using a relatively ... new look at the composition of carotid artery disease ... and treat the disease, a leading cause of stroke. ... Lexington between September 2010 and May 2012, was featured ... of the American College of Cardiology (JACC) Cardiovascular Interventions. ...
    (Date:9/30/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... Bridgewater, New Jersey location received ... Administration (FDA) relating to an inspection in June 2014 ... injectable, which was divested to Galderma S.A. in July ... contract manufacturers (rather than Valeant,s own internal manufacturing) with ...
    Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
    (Date:10/1/2014)... 01, 2014 Marriagelifeinsurance.com has released ... insurance for retired couples. , Senior citizens can ... security for their loved ones. A joint policy is ... persons pass away. , Life insurance can be ... insurance can even be purchased online, as the application ...
    (Date:10/1/2014)... (PRWEB) October 01, 2014 Lifeinsurance-policy.com ... find the best life insurance prices for smokers. , ... life insurance premiums. Comparing quotes is the best method ... finding quotes for customers who need coverage. , ... entire duration of the policy. Since the coverage is ...
    (Date:10/1/2014)... D.C. and ATLANTA (PRWEB) October 01, 2014 ... information security executive networking and relationship-marketing firm, ... 2014 Information Security Executive® and Project of ... include top-ranking decision makers representing organizations in ... academics. Projects include large-scale technology endeavors that ...
    (Date:10/1/2014)... genetic finding from Duke Medicine suggests that some people ... also be hard-wired to gain weight when exposed to ... An estimated 13 percent of people, all of whom ... this could help them reduce heart disease with simple ... management. , "Genetic susceptibility, psychosocial stress and metabolic factors ...
    (Date:10/1/2014)... 2014 Innovations announces the upcoming airing ... on Monday, October 20, 2014 at 7:30 a.m. EST/PT ... go behind the scenes to learn about Break the ... explore the practical help and information Break the Cycle ... warning signs of abuse, how to navigate the legal ...
    Breaking Medicine News(10 mins):Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2
    ... high efficiency particle air (HEPA) filters along with ... cardiovascular health, according to researchers in Denmark. In ... filters for just two days significantly improved a ... elderly individuals. , Reduction of particle exposure by ...
    ... Calif., Feb. 15 Concentric Medical,Inc., the global leader ... announced the addition of Kimberly Bridges to its,management team ... a $15 million,line of credit., "We are delighted ... President and CEO of Concentric Medical. "Concentric is,entering a ...
    ... who showed that a single prostate specific antigen (PSA) test ... prostate cancer up to 25 years later, (regardless of clinical ... used to predict advanced prostate cancer. , The findings, ... help physicians identify which men would benefit from intensive screening. ...
    ... RUTHERFORD, N.J., Feb. 14 Cambrex,Corporation (NYSE: CBM ) reports ... 2007., (Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO ), ... (-0.2% excluding foreign currency) compared to ... 6.7% (2.0% excluding foreign currency) compared to 2006. ...
    ... National Penn Bancshares Inc. (NASD:,NPBC) will replace Bradley Pharmaceuticals ... after the close of trading on Thursday, February 21, ... close on or about that date,pending final approvals., ... any relevant,updates on its website: http://www.standardandpoors.com ., ...
    ... The American people,through the U.S. Agency for ... program in Pakistan on child spacing and,reproductive health ... "FALAH is a visionary program that applies ... to deliver family planning services effectively and,explores new ...
    Cached Medicine News:Health News:Using HEPA filters may improve cardiovascular health 2Health News:Early warning: PSA testing can predict advanced prostate cancer 2Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 2Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 3Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 4Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 5Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 6Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 7Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 8Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 9Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 10Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 11Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 12Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 13Health News:Cambrex Reports Fourth Quarter and Full-Year 2007 Results 14Health News:Standard & Poor's Announces Change to U.S. Index 2
    ... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
    The narrow shaft and compact jaw design facilitates access and use in tight spaces, particularly useful in the posterior aspect of the knee....
    ... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
    ... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
    Medicine Products: